Thank you Flipper for your response and I hope that you are right in that the approval will not be appreciably delayed by the MHRA because if that regulator wishes to look at the preliminary results of the larger DCVax-L/Keytruda combo trial before submitting the MAA approval, it has the capacity to do that before December 1.